Senseonics initiates first-in-human study of Freedom CGM system

Senseonics announced it has initiated a first-in-human clinical study of its Freedom continuous glucose monitoring (CGM) system. The next-generation implantable device is designed to communicate directly with a mobile device, eliminating the need for the external on-body transmitter used by current CGM technology.

Detected & updated continuously · Source: Nebula